January 7, 2024
Mesenchymal stem cell therapy has been considered as a promising alternative approach for end-stage liver disease. Some clinical trials have confirmed the effectiveness of MSC therapy for liver disease, but its application has not been promoted and approved. There are still many issues that should be solved prior to using MSC therapy in clinical applications. The types of liver disease that are most suitable for MSC application should be determined, and the preparation and engraftment of MSCs should be standardized. These may be bottlenecks that limit the use of MSCs.
CellMex Research
MSC therapy for liver cirrhosis
Liver cirrhosis (LC) is a complication of liver disease that involves the loss of liver cells and irreversible scarring of the liver. In our research we’ve treated patients with cirrhosis caused by various forms of liver disease, such as chronic alcohol abuse, chronic viral hepatitis, primary biliary cirrhosis, autoimmune hepatitis (heterogeneous cirrhosis).
In our clinical studies and translational applications, over 363 of or our patients transplanted with MSC’s (mesenchymal stem cells) these patients showed significantly improved liver function, indicated by elevation of serum albumin levels, decrease in total serum bilirubin levels and decrease in sodium models on end-stage liver disease.
However, not all patients have revealed that MSC’s have the desired treatment effects on their specific liver cirrhosis. Of these patients not expressing positive improvement to MSC transplants; we re-analysed our research and placed them onto another form or stem cell; “Induced Pluripotent Stem Cells (iPSC’s) for treatment.
Our research shows that by using an alternative type of stem cell; the induced pluripotent stem cell, which are derived from skin, blood and adipose tissue; in our laboratory promotes the study to treat liver disease. We re-program these cells or induced them to become cells that are in an embryonic-like-state.
These cells can then be differentiated into becoming any cell type in the body. Our scientists have figured out how to mimic various stages of embryonic development to obtain stem cell-derived hepatocytes from iPS cells. These stem cell-derived cells have been shown to metabolize food, store energy, and eliminate toxins similarly to normal liver cells. These iPS cells can grow indefinitely in the lab and can potentially be used to generate large numbers of hepatocytes that could have clinical use as alternative liver treatments.
We transplant these stem cells using various available routes, most are transplanted by intravenous injection, with a direct intrahepatic injection and an intrasplenic injection.
Conclusions
According to our research, the efficacy of MSCs, iPSCs & ESC’s in the treatment of liver failure depends on its property of differentiation into hepatocyte-like cells.
Stem cell therapy has been regarded as a safe and promising therapeutic strategy for patients with end-stage liver disease, liver cirrhosis, liver failure and complications of post renal transplants. In addition to stem cell transplants, the use of unconventional gene-modified stem cells may be a promising and practical unmanipulated stem cells treatment.
Stem Cell Treatment of Liver Fibrosis & Cirrhosis:
Silvester Scott
Comprehensive Test
Follows Safety Protocol
Clinical Progress & Therapeutic Potential
Cost-effective treatment strategies for liver fibrosis or cirrhosis are limited. Many clinical trials of stem cells for liver disease shown that stem cells might be a potential therapeutic approach. We constantly review all published clinical trials of stem cells for the treatment of liver fibrosis / cirrhosis and provide our most recent overview of the most utilised cell sources, cell doses and transplant methods.
Furthermore, how stem cells play a therapeutic role in liver fibrosis, we are constantly researching any / all molecular mechanisms of stem cell treatment of liver fibrosis, liver regeneration, immunoregulation, myofibroblast repression and extracellular matrix degradation. Providing perspective for the future prospects of clinical implementation of stem cells.
Cell Therapy, the following are of particular concern:
- Cell Type
- Cell Number
- Route of Administration